Literature DB >> 15723623

Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.

C A Kontogiorgis1, P Papaioannou, D J Hadjipavlou-Litina.   

Abstract

The matrix metalloproteinases (MMPs) are a family of more than 20 enzymes that are intimately involved in tissue remodelling. These zinc-containing endopeptidases consist of several subsets of enzymes, including collagenase, stromelysins and gelatinases and are involved in the degradation of the extracellullar matrix (ECM) that forms the connective material between cells and around tissues. Disease processes associated with the MMPs are generally related to imbalance between the inhibition and activation of MMPs resulting in excessive degradation of the ECM. These indications include osteoarthritis rheumatoid arthritis, tumour metastasis and congestive heart failure. Inhibitors for these enzymes have been developed for the treatment of a starthingly wide array of disease process where matrix remodelling plays a key role. There are three major components to most MMP inhibitors- the zinc binding group ZBG, the peptidic backbone and the pocket occupying side chain. Most MMPs inhibitors are classified according to their ZBG. Inhibitors interactions at active-site zinc plays a critical role in defining the binding mode and relative inhibitor potency. The majority of MMP inhibitors reported in the literature contain an effective zinc binding group (e.g. hydroxamic acid, carboxylic acid, sulfhydryl group) that is either generally substituted with a peptide-like structure that mimics the substrates that they cleave or appended to smaller side chains that may interact with specific subsites (e.g., P1', P2', P3') within the active site. Although carboxylates exhibit weaker zinc binding properties than hydroxamates, they are known to show better oral bioavailability and are less prone to metabolic degradation. The expected loss of binding affinity after replacement of hydroxamates against carboxylates is faced by adequate choice of elongated S1' directed substituents. The need for novel selective MMP inhibitors makes them an attractive target for the QSAR and molecular modelling. 3-D QSAR models were derived using CoMFA, CoMSIA and GRID approaches leading to the identification of binding regions where steric, electronic or hydrophobic effects are important for affinity. Some structural requirements essential for achieving high binding affinity and selectivity are: an acidic unit tightly anchored through four contact points, bidentate chelation of Zn2+, carbonyl groups for hydrogen bonding, more than two extra units for hydrogen bonds, a hydrophobic moiety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723623     DOI: 10.2174/0929867053363243

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  17 in total

1.  Prediction of metalloproteinase family based on the concept of Chou's pseudo amino acid composition using a machine learning approach.

Authors:  Majid Mohammad Beigi; Mohaddeseh Behjati; Hassan Mohabatkar
Journal:  J Struct Funct Genomics       Date:  2011-12-03

2.  A profiling platform for the identification of selective metalloprotease inhibitors.

Authors:  Christophe Antczak; Constantin Radu; Hakim Djaballah
Journal:  J Biomol Screen       Date:  2008-03-18

3.  Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.

Authors:  Christophe Antczak; David Shum; Bhramdeo Bassit; Mark G Frattini; Yueming Li; Elisa de Stanchina; David A Scheinberg; Hakim Djaballah
Journal:  Bioorg Med Chem Lett       Date:  2011-06-12       Impact factor: 2.823

Review 4.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

5.  MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders.

Authors:  Yanyan Xing; Nicole Shepherd; Jie Lan; Wei Li; Sushmita Rane; Samir K Gupta; Shanxiang Zhang; Jun Dong; Qigui Yu
Journal:  Brain Behav Immun       Date:  2017-05-06       Impact factor: 7.217

6.  New biochemical insight of conserved water molecules at catalytic and structural Zn2+ ions in human matrix metalloproteinase-I: a study by MD-simulation.

Authors:  Bornali Chakrabarti; Hridoy R Bairagya; Bishnu P Mukhopadhyay; K Sekar
Journal:  J Mol Model       Date:  2017-02-04       Impact factor: 1.810

Review 7.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

8.  Expression of catalytically active matrix metalloproteinase-1 in dermal fibroblasts induces collagen fragmentation and functional alterations that resemble aged human skin.

Authors:  Wei Xia; Craig Hammerberg; Yong Li; Tianyuan He; Taihao Quan; John J Voorhees; Gary J Fisher
Journal:  Aging Cell       Date:  2013-05-15       Impact factor: 9.304

9.  Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.

Authors:  Yonghao Jin; Mark D Roycik; Dale B Bosco; Qiang Cao; Manuel H Constantino; Martin A Schwartz; Qing-Xiang Amy Sang
Journal:  J Med Chem       Date:  2013-05-16       Impact factor: 7.446

10.  Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.

Authors:  Quaovi H Sodji; Vishal Patil; James R Kornacki; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2013-12-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.